Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Insufficient enrollment potential
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Hoffmann-La Roche | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Patients who participated in the FUNCTION Study (Protocol WA19926) will be enrolled in this study. The investigators want to learn how long it takes Early Rheumatoid Arthritis patients who were treated with Tocilizumab to require treatment with another biologic medication.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Rate of Biologic Treatment | To describe the rate of requiring biologic treatment over 2 years following completion of the FUNCTION study | 2 years |
| Measure | Description | Time Frame |
|---|---|---|
| Treatment after completion of FUNCTION study | To determine the type of RA treatment regimen used by the treating physician upon completion of the FUNCTION study | Baseline |
| Rate of requiring treatment intensification |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients withdrawing first-line tocilizumab and/or methotrexate therapy due to therapeutic response during the FUNCTION (WA19926) study that have agreed to provide informed consent will be enrolled in this study.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Janet E Pope, MD, MPH, FRCPC | Pope Research Corp. | Principal Investigator |
| John S Sampalis, BSc, BA, MSc, PHD, FACE | JSS Medical Research Inc. | Principal Investigator |
Not provided
Not provided
| ID | Term |
|---|---|
| D001172 | Arthritis, Rheumatoid |
| ID | Term |
|---|---|
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
| D012216 | Rheumatic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
To determine the rate of requiring treatment intensification with a traditional DMARD(s) completion of the FUNCTION study. The durability of response after completion of the FUNCTION study. The clinical measures of disease progression over 2 years after completion of the FUNCTION study. The clinical measures of disease progression over 2 years after completion of the FUNCTION study.
| 2 years |
| Change in functional status | The change in patient-reported functional status over 2 years after tocilizumab withdrawal or maintaining Mtx or changing DMARD(s) | 2 years |
| Work productivity | To determine work productivity over 2 years after completion of the FUNCTION study | 2 years |
| Healthcare Utilization | To determine health-care utilization over 2 years after completion of the FUNCTION study | 2 years |
| D003240 |
| Connective Tissue Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |